Ironwood Pharmaceuticals (IRWD) Net Margin (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Net Margin data on file, last reported at 38.28% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 12915.0% year-over-year to 38.28%; the trailing twelve-month figure through Mar 2026 stood at 16.31% (down 5416.0% YoY), and the FY2025 full-year result was 46.3%, down 8996.0% from the prior year.
• Net Margin advanced to 38.28% in Q1 2026, from 342.54% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 170.96% in Q4 2024 to a low of 1014.62% in Q2 2023.
• A 5-year average of 59.18% and a median of 27.69% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin slumped 105276 bps in 2023 and soared 101371 bps in 2024, its largest moves.
• Tracing IRWD's Net Margin over 5 years: stood at 118.02% in 2022, then plunged by 205 bps to 123.77% in 2023, then surged by 238 bps to 170.96% in 2024, then tumbled by 300 bps to 342.54% in 2025, then jumped by 111 bps to 38.28% in 2026.
• Business Quant data shows IRWD's Net Margin at 38.28% in Q1 2026, 342.54% in Q4 2025, and 32.84% in Q3 2025.